what is a tirzepatide the Starting Dose for Weight Loss? What is the latest update

The prescription medication was formulated by Novo Nordisk and first received FDA approval for use as a type 2 diabetes treatment in December 5, 2017, resulting in the introduction of Ozempic as a once-weekly injectable GLP-1 receptor agonist designed to regulate blood sugar by enhancing insulin production

The FDA is tightening enforcement

Organoids were treated with 100 nM of progesterone (P4), 100 nM of levonorgestrel (L), 100 nM of semaglutide (S), or L+S for 72 h in organoid culture media (29, 30) containing 1 nM of estradiol as an additive to the media

doi:10.1016/j.diabres.2018.10.013

Semaglutide is technically called a GLP-1 receptor agonist

Cleland, W